Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$87.01M$87.01M+34.7% vs Q1 2018 Net Income-$76.64M-$76.64MN/M vs Q1 2018 EPS Diluted-$1.07-$1.07N/M vs Q1 2018 Operating Income-$76,387,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived-$162,496,000N/M Margins · derivedOperating margin-87.8%−40.2 pt vs Q1 2018
Net margin-88.1%−33.3 pt vs Q1 2018
ended Mar 31, 2019 · filed May 8, 2019 · 38 d after period end